Nina Shah, MD, discusses breakthroughs in the treatment of multiple myeloma throughout the preceding year.
Susan M. O'Brien, MD, discusses breakthroughs in the treatment of chronic lymphocytic leukemia throughout the preceding year.
Second-line treatment considerations for a 75-year-old man with high-risk primary myelofibrosis who was previously treated with ruxolitinib.
Second-line therapies for myelofibrosis that are available or in the pipeline for use.
The panel continues their conversation about the first patient case.
Toni Choueiri, MD, introduces the first patient case: a 65-year-old man with advanced-stage renal cell carcinoma.
Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.
Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.
An expert examines sequencing strategies for the treatment of metastatic prostate cancer.
Dr Aaron Berger shares updated safety data on next-generation androgen receptor inhibitors and impact of safety profile on treatment selection in nmCRPC.